

October 20, 1965

Dr. Vincent Y. Cremata, Jr.
Associate Director
Department of Clinical Research
Chas. Pfizer & Co., Inc.
Groton, Connecticut 06340

Dear Dr. Cremata:

Since returning from Groton, I have discussed the possibility of a study of thiothixene in our severe mentally ill patients. Studies of three other compounds are now in progress, but my associates believe that an evaluation of thiothixene would be possible during the next four to six months.

In our usual evaluation of compounds in this population, we have administered dosages recommended by other observers, and usually extended these into a higher dose range. The patients are maintained in small research wards with a psychiatrist and trained nurse observers in constant observation. We use rating scales, a copy of which is enclosed, which emphasize changes in various specified aspects of psychopathology. In addition, our program encompasses the examination of EEG changes since these have been of considerable help to us in determining the therapeutic efficacy of various compounds and the expected range of action.

During such a time period we can examine fifteen to twenty patients satisfactorily for periods of observation from two to five months. It has also been our habit to have a period of placebo administration prior to the administration of a new compound and this varies from three to eight weeks with an average of approximately five.

I would like the opportunity to discuss this with you in greater detail at your convenience.

October 20, 1965

I have also read the information on P-4599 and find this of considerable interest. Unfortunately, our patient population is heavily weighted with those with thought disorder and psychomotor disturbances, while mood and affect disturbances are generally less prominent. I am returning the folder of toxicology of P-4599 but I am taking the liberty of keeping the more general description for my records.

Again, may I thank you for the opportunity to visit your laboratories earlier this month.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp